Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Medical College of Wisconsin
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
BeBetter Med Inc
Washington University School of Medicine
University of Nebraska
Therapeutic Advances in Childhood Leukemia Consortium
Emory University
University of Washington
Fred Hutchinson Cancer Center
Weill Medical College of Cornell University
Zhejiang University
Weill Medical College of Cornell University
Therapeutic Advances in Childhood Leukemia Consortium
National Institutes of Health Clinical Center (CC)
National Cancer Centre, Singapore
Fred Hutchinson Cancer Center
Columbia University
AIDS Malignancy Consortium
City of Hope Medical Center
University of Maryland, Baltimore
Milton S. Hershey Medical Center
Gilead Sciences
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Singapore General Hospital
St. Jude Children's Research Hospital
Sanofi
Barbara Ann Karmanos Cancer Institute
University Hospital, Lille
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of California, San Francisco
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center